Comparison · NCT02246439-ce4e04eb
RHB-102 vs Placebo Oral Tablet: Number of Patients Returning to Emergency Department - ITT Population
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. RHB-102 vs Placebo Oral Tablet: Number of Patients Returning to Emergency Department - ITT Population. Trial comparisons, record NCT02246439-ce4e04eb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02246439-ce4e04eb
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0208 | 0.00813 | 0.0523 | wilson | |
| Risk in group 2 | 0.031 | 0.0121 | 0.077 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0102 | -0.0579 | 0.0266 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.672 | 0.171 | 2.64 | log | |
| Odds ratio, group 1 over group 2 | 0.665 | 0.163 | 2.71 | log | |
| Number needed to treat, for one fewer participant with the outcome on RHB-102 than on Placebo Oral Tablet | 98.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | RHB-102 | 1 tablet containing 6 mg immediate release and 18 mg sustained release ondansetron, once daily for up to 4 days. | 4 | 192 | OG000 |
| Group 2 | Placebo Oral Tablet | 1 tablet of matching placebo, once daily for up to 4 days. | 4 | 129 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients Returning to Emergency Department - ITT Population
- Description
- Proportion of patients returning to emergency department for gastrointestinal symptoms within 4 days of initial discharge
- Time frame
- Day 1 of Study - Day 5 of Study
- Population
Source ClinicalTrials.gov
Trial
- Title
- BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis
- NCT number
- NCT02246439
- Phases
- PHASE3
- Conditions
- Gastroenteritis, Gastritis
- Interventions
- RHB-102, Placebo Oral Tablet
- Lead sponsor
- RedHill Biopharma Limited
- Results first posted
- 2019-02-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02246439?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02246439-ce4e04eb